Kailera Therapeutics, Inc. (NASDAQ:KLRA) Given Average Rating of “Buy” by Brokerages

Kailera Therapeutics, Inc. (NASDAQ:KLRA) has been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $42.75.

A number of research analysts recently weighed in on the stock. Wall Street Zen lowered shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a report on Wednesday, May 13th. JPMorgan Chase & Co. assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price objective for the company. Leerink Partners assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 price objective for the company. Finally, Jefferies Financial Group assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price objective for the company.

Insider Buying and Selling at Kailera Therapeutics

In other Kailera Therapeutics news, major shareholder Rtw Investments, Lp acquired 500,000 shares of the business’s stock in a transaction on Monday, April 20th. The stock was bought at an average price of $16.00 per share, for a total transaction of $8,000,000.00. Following the acquisition, the insider owned 10,776,820 shares in the company, valued at approximately $172,429,120. The trade was a 4.87% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Andrew T. Kaplan acquired 8,398,438 shares of the business’s stock in a transaction on Monday, April 20th. The stock was acquired at an average price of $16.00 per share, with a total value of $134,375,008.00. Following the acquisition, the director owned 26,255,581 shares in the company, valued at $420,089,296. The trade was a 47.03% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders acquired 10,460,938 shares of company stock worth $167,375,008.

Kailera Therapeutics Stock Performance

Shares of Kailera Therapeutics stock opened at $22.03 on Wednesday. Kailera Therapeutics has a twelve month low of $18.50 and a twelve month high of $28.23. The company has a 50-day moving average of $21.72.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.